stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) EV/Sales
As of 6 November 2026, Dianthus Therapeutics, Inc. (DNTH) trades at a EV/Sales of 1,515×. Over the past ten years it has ranged from −40.6× (January 2024) to 2,947× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 583× | 706.09% |
| FY2024 | 72.3× | — |
| FY2023 | −40.6× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1,549× | (35.52%) |
| Jun 2026 | 2,403× | 9.95% |
| Mar 2026 | 2,185× | 274.80% |
| Dec 2025 | 583× | 65.47% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.9× |
| TVTX Travere Therapeutics, Inc. compare | 7.4× |
| CRSP CRISPR Therapeutics AG compare | 125× |
| COGT Cogent Biosciences, Inc. compare | 209× |
| DNTH Dianthus Therapeutics, Inc. | 1,515× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement